Clinical Rheumatology

, Volume 33, Issue 9, pp 1337–1340

Late-onset neutropenia following rituximab treatment for rheumatologic conditions

  • Gabriel S. Breuer
  • Michael Ehrenfeld
  • Itzhak Rosner
  • Alexandra Balbir-Gurman
  • Devy Zisman
  • Shirley Oren
  • Daphna Paran
Brief Report


Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of normal and malignant B lymphocytes. Its use in autoimmune conditions is rapidly expanding. Late-onset neutropenia (LON) is a well-recognized side effect of rituximab therapy in lymphoma patients. Only a small number of cases of LON have been reported in patients with autoimmune disorders. The aim of this work is to review cases in Israel and to compare them to published cases in the literature thus adding to the body of knowledge regarding this unusual phenomenon. Members of the Israeli Rheumatology Association were encountered by e-mail, requesting reports of cases of LON after therapy with rituximab. Submitted cases were reviewed, with demographics and clinical data collated and tabled. Current cases were compared to previously published rheumatology cases. Twelve episodes of LON following rituximab therapy were reported. All patients were female with an average age of 50 years (range 22–78). LON occurred at an average of 155 days after therapy (range 71–330). The average leukocyte count was1,456 white cells, with an average of 413 neutrophils (range 0–1,170 neutrophils). Three of the patients underwent bone marrow biopsies which showed white cell line maturation arrest with an increased number of lymphocytes. No blasts were seen. Our results add support to the growing evidence that this adverse event usually follows a benign course and is not an absolute contraindication for repeat treatment if required in the future. However, vigilance is recommended with routine periodic blood counts, especially 5 months following rituximab administration when the risk is expected to be the highest.


Autoimmune disease Neutropenia Rituximab 


  1. 1.
    Coiffier B (2007) Rituximab therapy in malignant lymphoma. Oncogene 26:3603–3613PubMedCrossRefGoogle Scholar
  2. 2.
    Edwards JCW, Szczepaniski L, Szechinski J et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 357:2572–2580CrossRefGoogle Scholar
  3. 3.
    Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54:613–620PubMedCrossRefGoogle Scholar
  4. 4.
    Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U, RAVE-ITN Research Group (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221–232PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363(3):211–220PubMedCrossRefGoogle Scholar
  6. 6.
    Berentsen S (2007) Rituximab for the treatment of autoimmune cytopenias. Haematologica 92:1589–1596PubMedCrossRefGoogle Scholar
  7. 7.
    Carr DR, Heffernan MP (2007) Off-label uses of rituximab in dermatology. Dermatol Ther 20:277–287PubMedCrossRefGoogle Scholar
  8. 8.
    Dörner T, Radbruch A, Burmester GR (2009) B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol 5(8):433–441PubMedCrossRefGoogle Scholar
  9. 9.
    Lemieux B, Tartas S, Traulle C et al (2004) Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant 33:921–923PubMedCrossRefGoogle Scholar
  10. 10.
    Wolach O, Bairey O, Lahaw M (2010) Late-onset neutropenia after rituximab treatment. Case series and comprehensive review of the literature. Medicine 89:308–318PubMedCrossRefGoogle Scholar
  11. 11.
    Besada E, Koldingsnes W, Nossent J (2012) Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. QJM 105(6):545–550PubMedCrossRefGoogle Scholar
  12. 12.
    Tesfa D, Ajeganova S, Hägglund H, Sander B, Fadeel B, Hafström I, Palmblad J (2011) Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 63(8):2209–2214PubMedCrossRefGoogle Scholar
  13. 13.
    Hincks I, Woodcock BE, Thachil J (2011) Is rituximab-induced late-onset neutropenia a good prognostic indicator in lymphoproliferative disorders? Br J Haematol 153:411–413PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2014

Authors and Affiliations

  • Gabriel S. Breuer
    • 1
  • Michael Ehrenfeld
    • 2
  • Itzhak Rosner
    • 3
    • 4
  • Alexandra Balbir-Gurman
    • 5
  • Devy Zisman
    • 6
  • Shirley Oren
    • 7
  • Daphna Paran
    • 8
  1. 1.Hebrew University School of MedicineShaare Zedek Medical CenterJerusalemIsrael
  2. 2.Chaim Sheba Medical CenterRamat GanIsrael
  3. 3.Bnai Zion Medical CenterHaifaIsrael
  4. 4.Faculty of Medicine, TechnionHaifaIsrael
  5. 5.Rambam Health Care CampusHaifaIsrael
  6. 6.Carmel Medical CenterHaifaIsrael
  7. 7.Rabin Medical CenterPetah TikvaIsrael
  8. 8.Tel Aviv Sourasky Medical CtrTel AvivIsrael

Personalised recommendations